Abbott Cuts Kaletra Price In Brazil
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug maker lowers price of lopinavir/ritonavir to $1,000 per patient per year in line with pricing for other low-middle income countries.
You may also be interested in...
Brazilian Government Authorizes Launch Of Generic Efavirenz
Country follows in the footsteps of Thailand, which issued a compulsory license for Merck’s HIV drug in November.
Abbott Cuts Kaletra Price In 40 Countries
Move follows spat between firm and Thailand over country’s decision to allow generic HIV therapies.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.